Dr. Sara Nunnery, director of breast cancer research at Tennessee Oncology, discusses the evolving classification of HER2-low and HER2-ultralow breast cancer, and the clinical implications of the DESTINY-Breast06 trial. She explains how precise pathology reporting is key to identifying eligible patients and offers insights into how Enhertu (trastuzumab deruxtecan) is changing treatment decisions in HR-positive, HER2-low metastatic breast cancer.
Breast Cancers Today
Breast Cancers Today features breaking news, commentary, expert interviews, and more updates to inform healthcare professionals on the latest research and best clinical practices in the breast cancer space.
Advertisement
Latest News
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.
Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.
Expert Interviews
Advertisement
Editorial Board
Stephanie L. Graff, MDEditor | Director of Breast Oncology, Brown University Health Cancer Institute
Rebecca Shatsky, MDEditor | Associate Professor of Medicine, Moores Cancer Center at the University of California, San Diego
Maryam Lustberg, MD, MPHEditor | Director of the Center for Breast Cancer, Smilow Cancer Hospital and Yale Cancer Center
Erika P. Hamilton, MDEditor | Director of Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute
Sarah Sammons, MDEditor | Associate Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.